Overcoming resistance to pathogens of vulvovaginal candidiasis using modern methods


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: The therapy of vulvovaginal candidiasis (V VC) still remains an unsolved issue. The development of the pharmaceutical industry and clinical studies conducted with the use of various antimycotic drugs have not provided the clear answers to the questions about the treatment of VVC. Research work in this sphere is relevant. Among other antimycotic drugs in the pharmacological market, sertaconazole appears to be promising. It has high eff iciency and safety indicators which are conf irmed by a number of studies; the data of the studies are presented in the article. Sertaconazole is a drug that has a triple effect on fungal pathogens: fungicidal and fungistatic action, as well as inhibition of dimorphic transformation (it blocks the transition of the fungus from a non-pathogenic to a pathogenic one which significantly increases the inter-relapse interval of VVC. Results: The therapeutic efficacy of sertaconazole was evaluated in 25 patients with chronic recurrent VVC. In all cases, the diagnosis of VVC was confirmed by clinical and laboratory methods, C. albicans was mainly identified in women. The patients received Zalain at a dose of300 mg once in the form of a vaginal suppository. No patients reported side effects after taking the drug. A day after the introduction of the suppository, 13 patients noted a significant improvement in their condition due to a decrease in itching and burning and 12patients noted the complete disappearance of symptoms of the disease. A week after the treatment, all patients’ symptoms of VVC were relieved; the results of the repeated cultural studies confirmed it. Conclusion: The treatment of VVC with a drug containing sertaconazole determines a successful outcome in the fight against the disease. It is important to use an integrated approach in its treatment and include adjuvant therapy which significantly accelerates recovery. Such therapy can also be used for the prevention aimed at reducing the likelihood of recurrent VVC and/or concomitant diseases of the genital tract.

Full Text

Restricted Access

About the authors

Asiyat Z. Khashukoeva

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: azk05@mail.ru
Dr. Med. Sci., Professor of the Department of Obstetrics and Gynecology

Marina V. Burdenko

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: bmv-0306@rambler.ru
PhD, Associate Professor, Department of Obstetrics and Gynecology, Deputy Dean of the Faculty of Additional Vocational Education

Eleonora A. Markova

Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: markova.eleonora@mail.ru
PhD, Assistant of the Department of Obstetrics and Gynecology

Tatyana Ye. Dmitrashko

Russian Clinical and Research Center of Gerontology, Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: lesnoy_elf@list.ru
obstetrician-gynaecologist

References

  1. Хашукоева А.З., Сафонина М.С., Андреасян Г.О., Мясоутова А.И., Оверко А.В. Терапевтические подходы в лечении вульвовагинального кандидоза. Медицинский совет. 2020; 13: 138-46. [Khashukoeva A.Z., Afonina M.S., Andreasyan G.O., Myasoutova A.I., Overko A.V. Therapeutic approaches in the treatment of vulvovaginal candidiasis. Medical Council. 2020; 13: 138-46. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2020-13-138-146.
  2. Rathod S.D., Buffler P.A. Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. BMC Women's Health. 2014; 14(1): 43. https://dx.doi.org/10.1186/1472-6874-14-43.
  3. Sobel J.D. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 2016; 214(1): 15-21. https://dx.doi.org/10.1016/j.ajog.2015.06.067.
  4. Байрамова Г.Р., Баранов И.И., Припутневич Т.В., Чернова В.Ф. Вульвовагинальный кандидоз: клинические и терапевтические аспекты в практике акушера-гинеколога. Акушерство и гинекология: новости, мнения, обучение. 2017; 4: 63-9.
  5. Abbasi Nejat Z., Farahyar S., Falahati M., Ashrafi Khozani M., Hosseini A.F., Faiazy A. et al. Molecular identification and antifungal susceptibility pattern of non-albicans Candida species isolated from vulvovaginal candidiasis. Iran. Biomed. J. 2017; 22(1): 33-41. https://dx.doi.org/10.22034/ibj.22.L33.
  6. Sobel J.D., Akins R.A. The role of PCR in the diagnosis of Candida vulvovaginitisea new gold standard? Curr. Infect. Dis. Rep. 2015; 17(6): 488. https://dx.doi.org/10.1007/s11908-015-0488-3.
  7. Mendling W., Brasch J., Cornely O.A., Effendy I., Friese K., Ginter-Hanselmayer G. et al. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses. 2015; 58(Suppl. 1): 1-15. https://dx.doi.org/10.1111/myc.12292.
  8. Fukazawa E.I., Witkin S.S., Robial R., Vinagre J.G., Baracat E.C., Linhares I.M. Influence of recurrent vulvovaginal candidiasis on quality of life issues. Arch. Gynecol. Obstet. 2019; 300(3): 647-50. https://dx.doi.org/10.1007/s00404-019-05228-3.
  9. Эфендиева З.Н. Сертаконазол в терапии вульвовагинального кандидоза. Медицинский совет. 2019; 13: 94-8. [Efendieva Z.N. Sertaconazole in the treatment of vulvovaginal candidiasis. Medical Council. 2019; 13: 94-8. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2019-13-94-98.
  10. Gonccalves B., Ferreira C., Alves C.T., Henriques M., Azeredo J., Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016; 42(6): 905-27. https://dx.doi.org/10.3109/1040841X.2015.1091805.
  11. Погосян Ш.М., Межевитинова Е.А., Донников А.Е., Муравьева В.В., Абакарова П.Р., Хлебкова Ю.С. Роль генотипических особенностей в развитии рецидивирующего вульвовагинального кандидоза и тактика терапии. Медицинский совет. 2017; 13: 172-9. https://dx.doi.org/10.21518/2079-701X-2017-13-172-179.
  12. Rosentul D.C., Delsing C.E., Jaeger M., Plantinga T.S., Oosting M., Costantini I. et al. Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Front. Microbiol. 2014; 5: 483. https://dx.doi.org/10.3389/fmicb.2014.00483.eCollection 2014.
  13. Plantinga T.S., Johnson M.D., Scott W.K., van de Vosse E., Velez Edwards D.R. et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 2012; 205(6): 934-43. https://dx.doi.org/10.1093/infdis/jir867.
  14. Ouederni M., Sanal O., Ikinciogullari A., Tezcan I., Dogu F., Sologuren I. et al. Clinical features of candidiasis in patients with inherited interleukin 12 receptor B1 deficiency. Clin. Infect. Dis. 2014; 58(2): 204-13. https://dx.doi.org/10.1093/cid/cit722.
  15. Куликов И.А. Перспективное лечение бесконечно повторяющегося вульвовагинального кандидоза. Медицинский совет. 2020; 13:157-65. [Kulikov I.A. Advanced therapy for eternal vulvovaginal candidiasis recurrences. Medical Council. 2020; 13: 157-65. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2020-13-157-165.
  16. Левчук И.П., Соков С.Л., Курочка А.В., Назаров А.П. Поражения кожи при болезнях внутренних органов: иллюстрированное руководство для врачей. 2-е изд. М.: ГЭОТАР-Медиа; 2020. 352с. [Levchuk I.P., Sokov S.L., Kurochka A.V., Nazarov A.P. Skin lesions in diseases of internal organs: an illustrated guide for doctors. 2nd ed., Moscow: GEOTAR-Media; 2020. 352 p. (in Russian)]. Available at: https://www.rosmedlib.ru/book/ ISBN9785970453797.html
  17. Прилепская В.Н., Абакарова П.Р., Байрамова Г.Р., Бурменская О.В., Довлетханова Э.Р., Донников А.Е., Здоровенко Т.Б., Коган Е.А., Козаченко А.В., Короткова Н.А., Костава М.Н., Ледина А.В., Межевитинова Е.А., Мгерян А.Н., Мзарелуа Г.М., Назаренко Е.Г., Назарова Н.М., Погосян П.М., Сычева Е.Г., Трофимов Д.Ю., Хлебкова Ю.С., Фофанова И.Ю., Чернова В.Ф., Шиляев А.Ю. Заболевания шейки матки и генитальные инфекции. М.: ГЭОТАР-Медиа; 2016. 384с. Available at: https://www.rosmedlib.ru/book/ ISBN9785970434062.html
  18. Лю басовская Л. А., Муравьева В. В., Шабанова Н.Е., Припутневич Т. В. Этиотропное лечение рецидивирующего вагинального кандидоза: выбор терапии - системная или местная. Медицинский совет. 2020; 13: 124-9. https://dx.doi.org/10.21518/2079-701X-2020-13-124-129.
  19. Szweda P., Gucwa K., Romanowska E., Dzierz Anowska-Fangrat K., Naumiuk L., Brillowska-Da A. et al. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland. J. Med. Microbiol. 2015; 64(6): 610-9. https://dx.doi.org/10.1099/jmm.0.000062.
  20. Гаспарян С.А., Хажбиев А.А., Рыжков В.В. Опыт применения сертако-назола у беременных с вульвовагинальным кандидозом. Медицинский гавет. 2019; 13: 160-5. [Gasparyan S.A., Habiev A.A., Ryzhkov V.V. Experience with the use of Itraconazole in pregnant women with vulvovaginal candidiasis. Medical Council. 2019; 13: 160-5. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2019-13-160-165.
  21. Rotem R., Fishman B., Daniel S., Koren G., Lunenfeld E., Levy A. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. BJOG. 2018; 125(12): 15501556. https://dx.doi.org/10.1111/1471-0528.15293.
  22. Selvan Т., Girisha G., Vijaybhaskar, Suthakaran R. Comparative evaluation of newer topical antifungal agents in the treatment of superficial fungal infections (tinea or dermatophytic). Int. Res. J. Pharmy. 2013; 4(6): 224-8. https://dx.doi.org/10.7897/2230-8407.04651.
  23. https://medvestnik.ru/content/medarticles/Mestnaya-etiotropnaya-terapiya-gribkovyh-porajenii-koji-i-slizistyh.html
  24. Кокоева Д.Н., Меджидова М.К., Домова Н.А., Кан Н.Е., Тютюнник В.Л. Профилактика преждевременных родов у беременных с вагинальным кандидозом. Медицинский совет. 2019; 7: 52-6. https://dx.doi.org/10.21518/2079701X-2019-7-52-56.
  25. Кашеваров Д.Ф., Воронцова И.В. Местная терапия вульвовагинального кандидоза. РМЖ. Мать и дитя. 2014; 19: 1394.
  26. Ипатова М.В., Маланова Т.Б. Медицинская реабилитация в гинекологии. В. кн.: Савельева Г.М., Сухих Г.Т., Серов В.Н., Радзинский В.Е., Манухин И.Б., ред. Гинекология. Национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2017: 785-97.
  27. Доброхотова Ю.Э., Боровкова Е.И., Бондаренко К.Р. Кандидозный вульво-вагинит: состояние изученности проблемы. Российский вестник акушера-гинеколога. 2017; 17(3): 108-11.
  28. Фадеев И.Е., Полетов а Т.Н., Масс Е.Е. Местный противогрибковый препарат сертаконазол: антимикотик резерва или средство первой линии эмпирической терапии вульвовагинитов? Consilium medicum. 2019; 21(6): 73-6. https://dx.doi.org/10/26442/20751753.2019.6.190558.
  29. Хашукоева А.З., Агаева З.А., Агаева М.И. Тактика снижения частоты рецидивов вагинального кандидоза у женщин со сниженным иммунитетом. Акушерство и гинекология. 2018; 12: 88-92. [Khashukoeva A.Z., Agaeva Z.A., Agaeva M.I. Tactics of reducing the frequency of recurrent vaginal candidiasis in women with reduced immunity. Obstetrics and Gynecology. 2018; 12: 88-92. (in Russian)]. https://dx.doi.org/10.18565/aig.2018(12):88-92.
  30. Aluyor E.O., Oboh I.O. Preservatives: traditional preservatives - vegetable oils. In: Encyclopedia of food microbiology. 2nd ed. Academic Press; 2014: 137-40. https://dx.doi.org/10.1016/B978-0-12-384730-0.00263-9.
  31. https://medvestnik.ru/content/medarticles/Vulvovaginalnyi-kandidoz-mnogo-voprosov-i-odin-otvet.html
  32. https://medvestnik.ru/content/medarticles/Algoritm-vedeniya-ginekologicheskoi-bolnoi-s-vulvovaginalnym-kandidozom.html

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies